Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
一期临床试验中基于贝叶斯模型平均的持续再评估法
The continual reassessment method (CRM) is a popular dose-finding design for phase I clinical trials. This method requires that practitioners prespecify the toxicity probability at each dose. Such prespecification can be arbitrary, and different specifications of toxicity probabilities may lead to very different design properties. To overcome the arbitrariness and further enhance the robustness of the design, we propose using multiple parallel CRM models, each with a…